Early personalized prediction for better brain health

Prodromic predicts disease trajectory early

Multimodal AI

We tackle the complexity of the brain by integrating different data sources

Designed for integration into trials and clinical workflows

Our AI approach is robust and explainable to provide the foundations for trust

Real world solutions

Responsible by design

Prodromic is redefining how the world understands, predicts and treats brain disorders. Built on a decade of research at the University of Cambridge, we're setting the new standard for predictive intelligence in dementia.

Dementia steals people and costs lives

A vast personal and societal problem ...

• Every 3 seconds someone new is diagnosed with dementia

• $1.3 Trillion cost to the global economy

• 3x more cases by 2050

... desperately in need of new solutions

• >95% failure rate for late-stage clinical trials

• >$43B pharma investment over 30 years

• "Approved - not used" - recent drugs withdrawn / challenged in market

Why is dementia such a challenge?

Dementia begins 'silently' around 10 to 15 years before cognitive decline is visible.

Traditional diagnostic methods often miss early pathology or confuse early symptoms with other conditions. This leads to:

• Around 25% of patients misdiagnosed

• Vague prognosis of "5 to 10 years until death"

• High failure rates >95% when testing new treatments

How does Prodromic help?

Our AI platform identifies which people are likely to remain stable with which are likely to decline—at the earliest stages of disease. By revealing signals hidden in the complexity of clinical data, we provide a continuous prediction score that transforms early triage, trial design and treatment development.

• Predict years ahead using standard clinical meausres

• Reduce uncertainty with interpretable, trustworthy AI

• Act sooner to deliver treatments when they can have the greatest impact

We're building partnerships to accelerate new treatments

Diseases such as dementia have huge human and societal cost. Progress in new treatments has been slow because we've been testing promising new drugs on (a) the wrong populations or (b) provided them too late.

We're working with clinicians, academics and pharmaceutical developers to accelerate the fight against brain diseases. By identifying suitable patients earlier in disease, Prodromic makes clinical trials faster, lower-cost, and more effective.